Electrically neutral group of two or more atoms
POPULARITY
Categories
70 episodes with molecular
100 episodes with molecular
22 episodes with molecular
113 episodes with molecular
27 episodes with molecular
57 episodes with molecular
33 episodes with molecular
21 episodes with molecular
15 episodes with molecular
45 episodes with molecular
33 episodes with molecular
27 episodes with molecular
20 episodes with molecular
19 episodes with molecular
10 episodes with molecular
16 episodes with molecular
19 episodes with molecular
15 episodes with molecular
13 episodes with molecular
12 episodes with molecular
23 episodes with molecular
15 episodes with molecular
9 episodes with molecular
12 episodes with molecular
13 episodes with molecular
17 episodes with molecular
8 episodes with molecular
9 episodes with molecular
4 episodes with molecular
6 episodes with molecular
8 episodes with molecular
7 episodes with molecular
4 episodes with molecular
5 episodes with molecular
8 episodes with molecular
9 episodes with molecular
6 episodes with molecular
11 episodes with molecular
5 episodes with molecular
40 episodes with molecular
17 episodes with molecular
6 episodes with molecular
8 episodes with molecular
12 episodes with molecular
9 episodes with molecular
7 episodes with molecular
6 episodes with molecular
5 episodes with molecular
5 episodes with molecular
7 episodes with molecular
7 episodes with molecular
8 episodes with molecular
22 episodes with molecular
22 episodes with molecular
3 episodes with molecular
6 episodes with molecular
6 episodes with molecular
6 episodes with molecular
7 episodes with molecular
7 episodes with molecular
4 episodes with molecular
7 episodes with molecular
9 episodes with molecular
4 episodes with molecular
2 episodes with molecular
5 episodes with molecular
6 episodes with molecular
6 episodes with molecular
9 episodes with molecular
6 episodes with molecular
5 episodes with molecular
13 episodes with molecular
4 episodes with molecular
7 episodes with molecular
3 episodes with molecular
2 episodes with molecular
6 episodes with molecular
6 episodes with molecular
2 episodes with molecular
7 episodes with molecular
4 episodes with molecular
3 episodes with molecular
4 episodes with molecular
5 episodes with molecular
4 episodes with molecular
3 episodes with molecular
5 episodes with molecular
3 episodes with molecular
4 episodes with molecular
73 episodes with molecular
4 episodes with molecular
3 episodes with molecular
2 episodes with molecular
3 episodes with molecular
4 episodes with molecular
3 episodes with molecular
3 episodes with molecular
2 episodes with molecular
6 episodes with molecular
3 episodes with molecular
5 episodes with molecular
5 episodes with molecular
3 episodes with molecular
3 episodes with molecular
3 episodes with molecular
6 episodes with molecular
2 episodes with molecular
4 episodes with molecular
2 episodes with molecular
5 episodes with molecular
2 episodes with molecular
5 episodes with molecular
5 episodes with molecular
4 episodes with molecular
2 episodes with molecular
5 episodes with molecular
6 episodes with molecular
Evolution Radio Show - Alles was du über Keto, Low Carb und Paleo wissen musst
Schau dir das Video zu dieser Folge an: Keto bei KREBS: Mythos oder Wahrheit? | Die ECHTE Wissenschaft der ketogenen Ernährung gegen KrebsYouTube Kanal gleich abonnieren und keine neue Folge mehr verpassenZusammenfassungIn dieser Episode räumt Julia Tulipan mit den Mythen rund um die ketogene Ernährung bei Krebs auf. Anstatt polarisierender Social-Media-Debatten liefert sie eine wissenschaftlich fundierte Analyse der Studienlage. Du erfährst, dass es nicht darum geht, den Tumor "auszuhungern", sondern um die komplexen Wirkmechanismen von Ketonen: Sie senken Blutzucker und Insulin, reduzieren Entzündungen, modulieren das Immunsystem und können gesunde Zellen schützen, während sie Tumorzellen für Therapien verwundbarer machen. Julia klärt die Fakten zum Warburg-Effekt (nicht widerlegt!) und zur metabolischen Flexibilität von Krebszellen. Sie entkräftet die Behauptung, Ketone würden Tumore füttern, und zeigt stattdessen die antitumorale Wirkung, die in vielen Studien beobachtet wird. Wir beleuchten vielversprechende klinische Studien zu Bauchspeicheldrüsen- und Brustkrebs, die zeigen, wie Keto in Kombination mit Standardtherapien die Krankheitsstabilität und Lebensqualität verbessern kann. Julias Fazit: Keto ist kein Allheilmittel, aber eine wissenschaftlich gut begründete, ergänzende Strategie, die die Wirksamkeit konventioneller Therapien unterstützen und Nebenwirkungen reduzieren kann. Eine professionelle Begleitung ist dabei unerlässlich.Was du in dieser Episode lernst
In this episode of the Epigenetics Podcast, we talked with Erica Korb from the University of Pennsylvania about her work on BRD4 and the histone variant H2BE, which influences synaptic genes and neuronal activity. Dr. Korb discusses the focus of her lab, which centers on epigenetic mechanisms impacting gene regulation in neurons. Her research primarily examines histone biology and its connection to neurodevelopmental disorders, including autism spectrum disorder and intellectual disabilities. Dr. Korb expounds on the collaborative environment at UPenn's Epigenetics Institute, emphasizing how the rich diversity of research topics fosters innovative ideas and projects within the community. Reflecting on her earlier work from her postdoctoral studies, Dr. Korb discusses her first significant findings regarding the protein BRD4. This work demonstrated BRD4's role in mediating transcriptional regulation crucial for learning and memory processes. She explains how disrupting this protein's function in neurons hindered critical gene activations required for memory formation in mice. This foundational understanding opened avenues for exploring the broader implications of chromatin regulation in various neurodevelopmental conditions. Transitioning into her current research endeavors, Dr. Korb reveals how she aims to expand her focus beyond Fragile X syndrome. With her lab now investigating multiple chromatin regulators implicated in various forms of autism spectrum disorders, she describes a recent project where RNA sequencing exposed substantial overlaps in gene expression changes associated with five distinct chromatin modifiers, each contributing uniquely to neuronal function while collectively demonstrating sensitivity to chromatin disruptions. A significant portion of the discussion centers around Dr. Korb's unexpected exploration into how COVID-19 intersects with chromatin biology through a phenomenon known as histone mimicry. Leveraging bioinformatic tools during the pandemic, her lab discovered that certain viral proteins mimic histone sequences, which may lead to altered transcriptional outputs in host cells. This coincidental finding illustrates both the creative adaptability needed in scientific research and the importance of collaborative efforts across disciplines to uncover new insights. The conversation also delves into Dr. Korb's recent work regarding the histone variant H2BE, initiated by one of her graduate students. She explains how prior research only recognized H2BE's expression in the olfactory system, yet her lab has demonstrated its significant role in regulating synaptic genes and memory formation throughout broader neuronal contexts. Notably, they identified a single amino acid change that influences H2BE's function in chromatin accessibility and gene transcription, emphasizing its potential evolutionary conservation across species. In terms of H2BE's role, Dr. Korb elucidates that its activity is integral in response to extracellular stimuli, particularly within the context of neuronal activation. Intriguingly, they found that H2BE expression decreases in reaction to long-term neuronal stimulation, suggesting a complex mechanism of homeostatic plasticity crucial for regulating neuronal activity levels. This research not only advances understanding of chromatin dynamics but also holds implications for neuronal health and disease mechanisms. References Feierman, E. R., Louzon, S., Prescott, N. A., Biaco, T., Gao, Q., Qiu, Q., Choi, K., Palozola, K. C., Voss, A. J., Mehta, S. D., Quaye, C. N., Lynch, K. T., Fuccillo, M. V., Wu, H., David, Y., & Korb, E. (2024). Histone variant H2BE enhances chromatin accessibility in neurons to promote synaptic gene expression and long-term memory. Molecular cell, 84(15), 2822–2837.e11. https://doi.org/10.1016/j.molcel.2024.06.025 Korb, E., Herre, M., Zucker-Scharff, I., Gresack, J., Allis, C. D., & Darnell, R. B. (2017). Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition. Cell, 170(6), 1209–1223.e20. https://doi.org/10.1016/j.cell.2017.07.033 Kee, J., Thudium, S., Renner, D. M., Glastad, K., Palozola, K., Zhang, Z., Li, Y., Lan, Y., Cesare, J., Poleshko, A., Kiseleva, A. A., Truitt, R., Cardenas-Diaz, F. L., Zhang, X., Xie, X., Kotton, D. N., Alysandratos, K. D., Epstein, J. A., Shi, P. Y., Yang, W., … Korb, E. (2022). SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry. Nature, 610(7931), 381–388. https://doi.org/10.1038/s41586-022-05282-z Feierman, E. R., Paranjapye, A., Su, S., Qiu, Q., Wu, H., & Korb, E. (2024). Histone variant H2BE controls activity-dependent gene expression and homeostatic scaling. bioRxiv : the preprint server for biology, 2024.11.01.620920. https://doi.org/10.1101/2024.11.01.620920 Related Episodes Neuroepigenetic Mechanisms and Primate Epigenome Evolution (Boyan Bonev) DNA Methylation Alterations in Neurodegenerative Diseases (Paula Desplats) The Role of Histone Dopaminylation and Serotinylation in Neuronal Plasticity (Ian Maze) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com
Kings of Anglia - Ipswich Town podcast from the EADT and Ipswich Star
Stuart Watson, Alex Jones, Mark Heath and Ross Halls are back with one of the biggest KOA pods of any year - our season preview! First, the boys chat about the latest transfer news, with Chuba Akpom and Jens Cajuste on the way in and Omari Hutchinson, Nathan Broadhead and Leif Davis all being linked with moves away. Then it's on to the main event - our big season preview. We predict who's going to be Town's leading scorer, MVP, surprise package and more - plus the big one, where Town will finish. There's still time for a look ahead to the season opener at Birmingham and our first predictions of the season, plus we welcome a new sponsor on board. Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk)
Send us a textDr. Reynold A. Panettieri, Jr, MD ( https://ritms.rutgers.edu/faculty/reynold-panettieri/ ) is the inaugural Director of the Institute for Translational Medicine and Science, and Vice Chancellor for Translational Medicine and Science, at Rutgers University, and previously served as the Director of the Airways Biology Initiative at the University of Pennsylvania. Dr. Panettieri's interests include the cellular and molecular mechanisms that regulate airway smooth muscle cell growth and the immunobiology of airway smooth muscle, which lead to the irreversible airflow obstruction and airway remodeling seen in patients with chronic severe asthma. Dr. Panettieri's lab also focuses on cytosolic signaling pathways that mediate gene expression and alter myocyte growth.Dr. Panettieri also served as the Deputy Director of the Center of Excellence in Environmental Toxicology at the University of Pennsylvania. He directed the human exposure chamber that defines the molecular mechanisms regulating ozone- and particulate matter-induced airway hyperresponsiveness.In addition to his research and clinical interests, Dr. Panettieri served as chairperson of the NIH Lung Cellular, Molecular, and Immunobiology Study Section, is a member of the NIH Distinguished Editorial Panel, and is a member of the American Society for Clinical Investigation and Association of American Physicians.Dr. Panettieri has an M.D. from University of Pennsylvania, and completed hisResidency and Fellowship at the Hospital of the University of Pennsylvania.Important Episode Links - As-Needed Albuterol–Budesonide in Mild AsthmaPublished May 19, 2025New England Journal Of Medicine -https://www.nejm.org/doi/full/10.1056/NEJMoa2504544BATURA Study Press Release - https://www.astrazeneca.com/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma.htmlAIRSUPRA (albuterol/budesonide) is a prescription medication used as a rescue inhaler for adults with asthma -https://www.airsupra.com/#ReynoldPanettieri #InstituteForTranslationalMedicineAndScience #RutgersUniversity #Asthma #COPD #ChronicObstructivePulmonaryDisease #AirwaysBiology #UniversityOfPennsylvania #Immunobiology #EnvironmentalHealth #Bronchiectasis #IdiopathicPulmonaryFibrosis #InterstitialLungDiseases #RescueInhalers #Albuterol #AIRSUPRA #Budesonide #Corticosteroid #BATURA #AstraZeneca #Exposome #RespiratoryDiseases #InflammatoryResponse #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
On this episode, Erik Wallenberg and Joshua Frank talk to Nafis Hasan about his new book, Metastasis: The Rise of the Cancer-Industrial Complex and the Horizons of Care. Nafis Hasan received his PhD in Cell, Molecular and Developmental Biology from Tufts University in 2019. He is currently an Associate Faculty at the Brooklyn Institute for More The post The Cancer-Industrial Complex w/ Nafis Hasan appeared first on CounterPunch.org.
The postglacial history of the Saimaa ringed seal Science Sessions are brief conversations with cutting-edge researchers, National Academy members, and policymakers as they discuss topics relevant to today's scientific community. Learn the behind-the-scenes story of work published in the Proceedings of the National Academy of Sciences (PNAS), plus a broad range of scientific news about discoveries that affect the world around us. In this episode, Jaakko Pohjoismäki, Jukka Jernvall, and Ari Löytynoja discuss the evolutionary history of the Saimaa ringed seal. In this episode, we cover: •[00:00] Introduction •[01:06] Molecular biologist Jaakko Pohjoismäki introduces Lake Saimaa and the Saimaa ringed seal. •[02:30] Zoologist Jukka Jernvall talks about the characteristics of species isolated by glaciation. •[03:27] Evolutionary biologist and bioinformatician Ari Löytynoja explains the genetic and demographic methods of the study. •[04:11] Löytynoja and Jernvall explain why the results were surprising and where the study turned next. •[06:20] Pohjoismäki and Löytynoja describe the study's implications for biodiversity in postglacial habitats. •[07:50] Jernvall and Löytynoja talk about the study's caveats and limitations. •[10:14] Conclusion. About Our Guests: Jaakko Pohjoismäki Professor University of Eastern Finland Jukka Jernvall Professor University of Helsinki Ari Löytynoja University Lecturer University of Helsinki View related content here: https://www.pnas.org/doi/abs/10.1073/pnas.2503368122 Follow us on Spotify, Apple Podcasts, or wherever you get your podcasts for more captivating discussions on scientific breakthroughs! Visit Science Sessions on PNAS.org: https://www.pnas.org/about/science-sessions-podcast Follow PNAS: Twitter/X Facebook LinkedIn YouTube Sign up for the PNAS Highlights newsletter
En Ivoox puedes encontrar sólo algunos de los audios de Mindalia. Para escuchar las 4 grabaciones diarias que publicamos entra en https://www.mindaliatelevision.com. Si deseas ver el vídeo perteneciente a este audio, pincha aquí: https://www.youtube.com/watch?v=3Q4upx_TOPI Cada persona sintoniza con diferentes energías según su frecuencia: guías, ángeles, maestros, animales de poder... Descubre cómo ir más allá de los sentidos, soltar el ruido mental y confiar en tu percepción. Expandir tu intuición te permite conectar con tus Guías, recibir claridad y direccionar tu camino. Patricia Poustkova Doctora en Genética Molecular, formada con maestros internacionales en percepción, canalización y mediumnidad. Hoy es Médium, Terapeuta Energética y Mentora para desarrollar tu percepción y conectar con el mundo sutil. https://www.almahealing.net / _almahealing Más información en: https://www.mindalia.com/television/ PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. ------------INFORMACIÓN SOBRE MINDALIA----------DPM Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS Facebook: / mindalia.ayuda Instagram: / mindalia_com Twitch: / mindaliacom Odysee: https://odysee.com/@Mindalia.com *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas.
En Ivoox puedes encontrar sólo algunos de los audios de Mindalia. Para escuchar las 4 grabaciones diarias que publicamos entra en https://www.mindaliatelevision.com. Si deseas ver el vídeo perteneciente a este audio, pincha aquí: https://www.youtube.com/watch?v=3Q4upx_TOPI Cada persona sintoniza con diferentes energías según su frecuencia: guías, ángeles, maestros, animales de poder... Descubre cómo ir más allá de los sentidos, soltar el ruido mental y confiar en tu percepción. Expandir tu intuición te permite conectar con tus Guías, recibir claridad y direccionar tu camino. Patricia Poustkova Doctora en Genética Molecular, formada con maestros internacionales en percepción, canalización y mediumnidad. Hoy es Médium, Terapeuta Energética y Mentora para desarrollar tu percepción y conectar con el mundo sutil. https://www.almahealing.net / _almahealing Más información en: https://www.mindalia.com/television/ PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. ------------INFORMACIÓN SOBRE MINDALIA----------DPM Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS Facebook: / mindalia.ayuda Instagram: / mindalia_com Twitch: / mindaliacom Odysee: https://odysee.com/@Mindalia.com *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas.
Send us a textThe future of cancer treatment is on the horizon, but can we afford it, regulate it, and deliver it at scale?In this episode of the HealthBiz Podcast, Dr. Jason Bock, Co-founder and CEO of CTMC, discusses the progress of CAR T cell therapy, the challenges of scaling manufacturing for personalized treatments, and how new payment and policy models can support broader access. He shares inspiring patient success stories, insights into the future of solid tumor therapies, and CTMC's mission to bring advanced therapies to more patients, faster.
Hosts Roz and Alberto are joined by new Editorial Fellow Dr. Sofia Bin to discuss the key articles of the August issue of the American Journal of Transplantation. Dr. Sofia Bin is an assistant professor of medical and surgical sciences at the University of Bologna. [02:46] Gut microbiome alterations precede graft rejection in kidney transplantation patients [10:31] Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: a multicenter international study Editorial: Graft biopsy reimagined: Integrating morphology and molecular maps [22:20] Does a changing donor pool explain the recent rise in the United States kidney nonuse rate? [32:45] A scintigraphic look at the dead donor rule in donation after the circulatory determination of death with the use of normothermic regional perfusion: A single-center interventional trial Editorial: Normothermic regional perfusion in donation after circulatory determination of death—Confirming the absence of brain reperfusion [37:03] Global variation in living donor liver transplantation practices impacts donor and recipient short-term outcomes: initial insights from the International LDLT Registry
Microcosmos Records presents a meditative electronic journey, the album Panta Rhei by Jule Grasz. Jule Grasz (Germany) began composing music in early childhood. In the 1990s, she wrote songs while collaborating with various artists. In 2006, she discovered the world of electronic music production, and since 2008, she has been successfully releasing her chillout music on multiple labels, including Microcosmos Records. Panta Rhei in Ancient Greek means "Everything flows". As Jule herself describes, the album is a musical interpretation of the philosophical principle of perpetual change as the foundation of existence: «Everything comes into being, everything is one, everything flows, everything passes away, in an eternal metamorphosis of being.» The tracks radiate optimism and joy. Artfully textured soundscapes evoke an ever-changing eternity of the cosmos, while hypnotic arpeggios guide listeners through intricate sonic corridors like winding staircases. Press play on Panta Rhei and immerse yourself in the unhurried flow of refined chillout music by Jule Grasz and Microcosmos Records.
Send us a textDr. Ashwin Gopinath, Ph.D. ( https://ashwingopinath.com/ ) is Co-Founder and CTO of Biostate AI ( https://biostate.ai/ ), a startup building generative AI that predicts the evolution of human disease and drug response based on RNA sequencing data. Its patented wet lab technologies, including BIRT (Barcode-Integrated Reverse Transcription), allow affordable and scalable collection of massive amounts of transcriptomic and genomic data. With sites in Houston, TX, Palo Alto, CA, Bangalore, India, and Shanghai, China, Biostate AI is an international company with collaborations with top hospitals, academic researchers, and biotech/biopharma companies. Dr. Gopinath was an Assistant Professor at MIT, working at the intersection of CMOS nanofabrication, molecular self-assembly, biology, and machine learning.Dr. Gopinath earned his Ph.D. in Electrical Engineering from Boston University, and subsequently worked as a research scientist at Caltech and Google [X].Dr. Gopinath has co-authored over 21 papers in journals including Nature, Science, and the Proceedings of the National Academy of Sciences (PNAS).Dr. Gopinath was awarded the 2017 Robert Dirk Prize in Molecular programming for his contributions to merging DND nanotechnology with conventional semiconductor processing.#AshwinGopinath #BiostateAI #GenerativeAI #RNASequencing #OpticalPhysics #DNANanotechnology #DNAOrigami #MolecularDiagnostics #RNAseq #GenAI #Leukemia #MultipleSclerosis #Reactome #TranscriptomicAgePrediction #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
Show notes: (0:00) Intro (1:12) Nagina's struggle and breakthrough (5:09) Energy in midlife (6:44) #1 reason women can't lose weight in midlife (11:51) Why food, not workouts, is key to a faster metabolism (15:10) Fat-burning breakfast tips: protein, fiber, and healthy fats (23:12) Swapping hidden sugar bombs for better choices (28:05) Making your smoothies (33:01) Cinnamon, vinegar, and other blood sugar-lowering tricks (42:10) Free gifts and how to connect with Nagina directly (45:48) Outro Who is Nagina Abdullah? Nagina Abdullah is a weight loss coach for women in midlife and the founder of the top-rated website MasalaBody.com. She holds a degree in Molecular and Cell Biology from UC Berkeley and earned her MBA from NYU. After personally losing 40 pounds by naturally boosting her metabolism, she began helping other women—especially those over 40—achieve lasting weight loss without extreme dieting or restriction. Over the past several years, she has coached more than 1,600 women to slim down, reduce belly fat, increase their energy, and regain confidence in their bodies. Nagina's signature approach focuses on adding metabolism-boosting foods, not cutting calories, and her science-backed methods have helped thousands transform their lifestyles for good. Connect with Nagina: Website: https://masalabody.com/ IG: https://instagram.com/masalabody DM “sweet” on IG to get the Free Sweet Spice Cheat Sheet Schedule a Free Midlife Metabolism Discovery Call: https://www.masalabody.com/apply Links and Resources: Peak Performance Life Peak Performance on Facebook Peak Performance on Instagram
Dr. Ganesh Anand is an Associate Professor of Chemistry as well as Biochemistry and Molecular Biology at The Pennsylvania State University (or Penn State University) at the University Park campus. He is also an elected Board Member of the International Society for Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS). Research in Ganesh's lab examines molecular switches. He wants to know how molecules interact with one another and how they switch from one state to another. These tiny molecular switches act almost like electrical switches turning on and off the functions of different molecules. He also does research on viruses and how they change shape to infect their hosts. Beyond his scientific interests, Ganesh has also been passionate about music for as long as he can remember. He takes voice lessons now and enjoys singing in choirs in his free time. He received his bachelor's degree in pharmacy and his master's degree in biological sciences from Birla Institute of Technology and Science in India. Next, Ganesh attended Rutgers University where he earned his PhD in biochemistry. Afterwards, he conducted postdoctoral research as a Howard Hughes Medical Institute Research Fellow at the University of California San Diego. Ganesh served on the faculty in the Department of Biological Sciences at the National University of Singapore for over a decade before accepting a faculty position at Penn State where he is today. His lab is recognized as a Waters World Center of Innovation in Hydrogen/Deuterium Exchange Mass Spectrometry. Ganesh is founding member and former Director of the Singapore National Laboratory for Mass Spectrometry (SingMass) and the former Vice President of the Singapore Society for Mass Spectrometry. In this interview, he shares more about his life and science.
In today's OncClub episode, we had the pleasure of speaking with Branden Moriarity, PhD; and Beau Webber, PhD, about a study evaluating neoantigen-reactive CISH knockout tumor-infiltrating lymphocyte (TIL) therapy in patients with metastatic gastrointestinal cancers. Dr Moriarity is an associate professor in the Division of Pediatric Hematology/Oncology, co-director of the Center for Genome Engineering and the Genome Engineering Shared Resource (GESR), and a member of the Center for Genome Engineering at the University of Minnesota in Minneapolis, where he is also a faculty member in the Department of Pediatrics; the Microbiology, Immunology and Cancer Biology (MICaB) PhD Graduate Program; the PhD Program in Molecular, Cellular, Developmental Biology and Genetics; the Cellular and Molecular Biology (CMB) Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Stem Cell Institute at the Masonic Cancer Center. Dr Webber is an associate professor in the Division of Pediatric Hematology/Oncology, co-director of the GESR, and a member of the Stem Cell Institute at the University of Minnesota Medical School, where he is also a faculty member in the Department of Pediatrics, the Molecular Pharmacology & Therapeutics Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Masonic Cancer Center. In our exclusive interview, Drs Moriarity and Webber discussed how targeting the CISH gene using CRISPR enhances T-cell function, key safety and efficacy findings from this study in 12 patients, and future research efforts that may focus on reducing manufacturing time and cost, as well as enhancing T-cell resilience. Check out the full OncClub subseries to see additional findings and insights from this research!
At the 2025 Kidney Cancer Research Summit hosted by KidneyCAN, CancerNetwork® spoke with a variety of leading experts about key developments in the research and management of kidney cancer. Throughout the meeting, presenters shared their findings related to updated clinical trial results, personalized cancer vaccines, potential biomarkers of interest, and other advancements in the field. Thomas Powles, MBBS, MCRP, MD, discussed outcomes from a quality-adjusted survival time without symptoms or toxicity (Q-TWiST) analysis of the phase 3 LITESPARK-005 trial (NCT04195750), in which investigators evaluated treatment with belzutifan (Welireg) vs everolimus (Afinitor) among patients with advanced renal cell carcinoma (RCC). Powles, a professor of genitourinary oncology, lead for Solid Tumor Research, and director of Barts Cancer Institute at St. Bartholomew's Hospital, Queen Mary University of London, stated that these data demonstrate how belzutifan is more active and better tolerated than everolimus in this patient population. David A. Braun, MD, PhD, assistant professor at Yale School of Medicine and member of the Center of Molecular and Cellular Oncology within the Yale Cancer Center, detailed his presentation on a personalized neoantigen cancer vaccine as a treatment for those with RCC. Based on his presentation, Braun highlighted how neoantigen vaccines may effectively yield T-cell responses in patients, illustrating a need for additional, larger studies to elucidate the clinical activity of this modality in an adjuvant setting. Additionally, Wenxin (Vincent) Xu, MD, a medical oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, spoke about his presentation on how kidney injury molecule-1 (KIM-1) may serve as a prognostic biomarker of response to therapy in patients with RCC. His research posed questions on how KIM-1 can inform the use of adjuvant therapy or specific therapeutic combinations like nivolumab (Opdivo) plus ipilimumab (Yervoy) for this patient population. Eric Jonasch, MD, gave an overview of his presentation focused on the Kidney Cancer Research Consortium, a research partnership spanning 7 institutions dedicated to facilitating mechanistic, hypothesis-testing clinical trials in RCC. Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, described how this collaboration aims to link identifiable biological characteristics of RCC subtypes to specific treatment strategies while developing predictive biomarkers. KidneyCAN is a nonprofit organization with a mission to accelerate cures for kidney cancer through education, advocacy, and research funding. You can learn more about KidneyCAN's work here: https://kidneycan.org/ References 1. Powles T, de Velasco G, Choueiri TK, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005). Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. Abstract 13. 2. Braun DA. Personalized vaccines in kidney cancer: a journey from concept to clinic. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 3. Xu W. From bench to bedside: advancing KIM-1 as a tool for clinical decision-making. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 4. Jonasch E. Building the infrastructure for discovery: a clinical trial consortium to accelerate kidney cancer research. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.
Entrevista com o professor Eduardo Ramalho, coordenador do Laboratório de Genética Molecular
Dr. Eric Balcavage interviews Nagina Abdullah about why traditional weight loss approaches fail for women with thyroid issues, especially in midlife. Nagina shares her personal journey from yo-yo dieting to losing 40 pounds using metabolism-focused strategies and reveals the framework she's used to help 1600+ women. Key Topics Covered: Why "calories in, calories out" doesn't work in midlife How perimenopause changes metabolism and increases inflammation The role of stress, sleep, and under-eating in weight gain Nagina's "Tested & Perfected Fat Burning Food Framework" Specific macro ratios: 40% protein, 35% healthy fats, 25% healthy carbs When to use advanced strategies like "feeding up" and intermittent fasting Why thyroid patients need digestive support and adequate carbohydrates The connection between liver function and T4 to T3 conversion Perfect for: Women over 40 struggling with weight despite "doing everything right," especially those with thyroid conditions seeking practical, science-based nutrition strategies. Nagina Abdullah is the founder of MasalaBody. She is the metabolism expert for midlife women who feel like their bodies have turned against them. When nothing else works, she helps them fire up their metabolism, burn stubborn fat, and finally see results. After maintaining a 40-pound weight loss for over a decade, she used her Bloat Busting Protocol to shed 14 pounds of perimenopause weight. With a degree in Molecular and Cell Biology from UC Berkeley & an MBA from NYU, she blends scientific research with practical strategies to help midlife women boost their metabolism, shed stubborn weight, and create a sustainable, healthy lifestyle. While most midlife women are told to "eat less and exercise more," Nagina does the opposite. She replaces restriction with metabolism-boosting foods that melt belly fat & make healthy living effortless. Her proven methods have helped 1,600+ women finally break free from stubborn midlife weight, without frustration or deprivation. Guest Links & Resources:
In today's episode, we explore the groundbreaking intersection of addiction, biology, and cancer with internationally recognized scientist Dr. Rafael Cuomo. Drawing on insights from his book Crave, Dr. Cuomo reveals how addiction is not simply a behavioral or psychological issue—it's a biological condition that reshapes the terrain of our health and directly contributes to the development of chronic disease, including cancer. Dr. Cuomo introduces the concept of “molecular scars”—long-term physiological changes left behind by repeated addictive behaviors, even low-grade ones like screen use or ultra-processed food consumption. He explains how these behaviors disrupt key systems in the body, including the dopamine, opioid, GABA, glutamate, cortisol, and the endocannabinoid systems, ultimately weakening immune surveillance, fueling inflammation, and accelerating cellular damage. From the anticipatory nature of craving to the role of trauma and adverse childhood experiences, this episode invites clinicians, patients, and everyday listeners to reconsider addiction not as a character flaw, but as a biologically driven imbalance with profound public health implications.
Before adjusting your thyroid meds, have you ever ruled out gut-based triggers?Gut imbalances can have a bigger impact on thyroid health than most realize, especially in autoimmune conditions like Graves' and Hashimoto's. When the gut barrier breaks down, the immune system can get confused and prevent symptoms from fully improving. Testing can also be tricky, and just because something shows up doesn't always mean it needs to be treated. In this episode, I walk through how I approach these situations; how to evaluate critically, when to dig deeper, and when the priority should be foundational support like stress, sleep, and diet.Tune in to get a clearer picture of how gut health could be influencing your thyroid!Episode Timeline: 00:00 – Introduction to the Question00:08 – How infections can impact gut and thyroid function01:15 – Molecular mimicry and immune confusion01:35 – Infections and overgrowths that may influence autoimmunity02:36 – Testing methods and treatment preferences03:39 – Parasite treatment debates and false negatives05:07 – Why root cause work goes beyond infection treatment06:03 – Episode Wrap up06:40 – Podcast OutroFree resources for your thyroid healthGet your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.comHigh-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Access hundreds of free articles at www.NaturalEndocrineSolutions.com Visit Dr. Eric's YouTube channel at www.youtube.com/c/NaturalThyroidDoctor/ To work with Dr. Eric, visit https://savemythyroid.com/work-with-dr-eric/
Are you a woman leader or entrepreneur considering a career pivot, especially from academia to the dynamic startup world? Do you wonder how to navigate this transition, build crucial relationships, and drive innovation in a new industry? This episode of How Women Inspire addresses these very challenges, offering invaluable insights into making a successful leap and fostering meaningful connections.This week's episode 177 of How Women Inspire Podcast is about transitioning from academia to startups! In this episode of How Women Inspire Podcast, Grace Wei is sharing the importance of building relationships and maintaining connections with experts and mentors. and actionable steps you can take right now to build a team culture at your startup. Grace Wei has held the position of COO at Encellin since 2016. Prior to that, Grace worked as a biologist at UCSF from 2005 to 2015. Grace Wei has a Bachelor's Degree in Human Genetics from McGill University and a Ph.D. in Molecular and Cellular Biology from the University of Chicago. Grace also completed programs at Stanford University Graduate School of Business and Y Combinator.Some of the talking points Julie and Grace go over in this episode include:Why building and maintaining strong relationships is paramount for founders and leadersThe unique benefits of different accelerators and how they can provide access to experts, community, and professional coaching for your startup journey.How transitioning from a specialized field like academia to a startup environment requires humility and a willingness to seek adviceThe importance of team culture for startup success, and how that differs from academia.What steps will you take today to cultivate your network and embrace new challenges?Thank you for listening! If you enjoyed this episode, take a screenshot of the episode to post in your stories and tag me! And don't forget to follow, rate, and review the podcast and tell me your key takeaways!Learn more about How Women Inspire at https://www.howwomenlead.com/podcast CONNECT WITH GRACE WEI:LinkedInEncellinCONNECT WITH JULIE CASTRO ABRAMS:LinkedIn - JulieHow Women LeadHow Women InvestHow Women GiveInstagram - HWLLinkedIn - HWLFacebook - HWL
Two Women Inspiring Real Life with Stephanie Coxon and Kathy Anderson-Martin – Leaked memos suggest some want Robert F. Kennedy Jr. out as Secretary of Health & Human Services. Molecular biologist Dr. James Lyons-Weiler joins us to discuss who's behind this and why. We explore the trillion-dollar vaccine industry, informed consent, and the importance of critical thinking for your family's health...
Welcome back to today's Friday Review where I'll be breaking down the best of the week! I'll be sharing specifics on these topics: The Well-Lived Life (book review) Your First Lab Program (product review) “Molecular Jackhammers” & Cancer (research) For all the details tune in to today's Cabral Concept 3444 – Enjoy the show and let me know what you thought! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3444 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
Older feeds The Nuclear Medicine and Molecular Medicine podcast-
WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}
Older feeds The Nuclear Medicine and Molecular Medicine podcast-
WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}
WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}
WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}
Dr. Michelle Starz-Gaiano is Professor and Chair of Biological Sciences at the University of Maryland Baltimore County (UMBC). Michelle's research uses fruit flies to examine how cells in the body go to the right place at the right time. Understanding why and how cells use their genetic information to move through the body is critical because if this movement doesn't happen correctly, it could, for example, impact embryo development or affect how immune cells mobilize after an injury. Conversely, preventing cancer cells from moving could keep cancer from spreading to other parts of the body. Michelle often spends her free time cooking and baking. Her kitchen looks a little like a lab, and she enjoys experimenting with making different foods. Michelle and her family also like to spend time together, travel, and listen to music. She received her bachelor's degree in biology from the Massachusetts Institute of Technology and her PhD in Developmental Genetics from New York University. Afterwards, Michelle completed a postdoctoral fellowship at Johns Hopkins School of Medicine. She joined UMBC in 2008 and has received the Donald Creighton Outstanding Faculty Member Award from the UMBC Graduate Student Association for her excellent mentorship. In our interview, she shares more about her life and science.
About Nagina Abdullah: Nagina Abdullah is a weight-loss coach for women in midlife and founder of the top-rated website MasalaBody.com. Nagina has a degree in Molecular and Cell Biology from UC Berkeley and earned an MBA at NYU. She has helped more than 1,500 women in midlife successfully lose weight permanently and create a lifestyle change. Nagina teaches women to boost their metabolism naturally to burn fat even when nothing else has worked. She focuses on adding and combining natural metabolism-boosting foods to reduce belly fat and get women unstuck so that they can live in their dream body. What We Discuss In This Episode: The "Add, Don't Subtract" Method: How Eating More Helps Midlife Women Lose More Weight How to Debloat, Reduce Inflammation, & Burn Fat Naturally (Even After Menopause) How to Get Off Sugar with the 4-Part Fat-Burning Food Framework (While Still Enjoying Chocolate Cake!) How to Boost Metabolism to Lose Weight (Without Calorie Counting or Dieting) How to Boost Your Metabolism in Midlife by Adding, Timing, and Pairing Foods Free Resource From Nagina Abdullah: Sweet Spice Cheat Sheet, which reveals the spice in your kitchen that helps curb sugar cravings and lower blood sugar—naturally. It includes: 3 powerful health benefits of this spice 5 simple ways to use it daily 1 easy recipe to get started
BUFFALO, NY – June 27, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.” In this study, researchers led by first authors Cleto Dantas Nogueira from the Federal University of Ceará and Argos Pathology Laboratory and Samuel Frota from Argos Pathology Laboratory, along with corresponding author Fabio Tavora from the previously mentioned institutions and Messejana Heart and Lung Hospital, investigated how HER2 gene mutations appear in cases of non-small cell lung cancer (NSCLC) in Northeastern Brazil. The team found that HER2 mutations showed significant genetic diversity and were often associated with other cancer-related genetic changes. These findings revealed diagnostic and treatment challenges in a population that is rarely studied, emphasizing the need for expanded access to molecular testing and targeted therapies. HER2 mutations are a known factor in several cancers, including breast and gastric cancers. In lung cancer—particularly NSCLC—these mutations are less common but remain clinically significant. Most existing research on HER2-mutated lung cancer focuses on high-income countries, leaving important gaps in knowledge about underrepresented regions such as Latin America. This study helps fill that gap by analyzing 13 patients with HER2-mutated NSCLC using clinical, pathological, and genomic data. The patients ranged in age from 34 to 82 years, and more than half were women. About half had never smoked. Their tumors often displayed complex genetic profiles, including additional mutations in genes such as TP53, KRAS, and STK11. The most common HER2 mutation identified was an insertion in exon 20, a known hotspot for activating mutations. “Trastuzumab deruxtecan (T-DXd) is the first HER2-targeted agent to show clinical efficacy in HER2-mutant non-small cell lung cancer (HER2m NSCLC).” Treatment strategies among the patients varied. Only one individual received HER2-targeted therapy. Most were treated with surgery, chemotherapy, immunotherapy, or a combination of these approaches. Outcomes also differed, with some patients surviving for years and others dying within months of diagnosis. These findings reinforce the need for early diagnosis and improved access to advanced treatments, particularly in low-resource settings. The study emphasizes the value of comprehensive molecular profiling in NSCLC. Because HER2 mutations often occur alongside other genetic alterations, full genomic analysis is crucial for guiding treatment decisions. Yet, such testing is not always available. The researchers propose a tiered diagnostic approach, beginning with basic screening and expanding to more advanced tests when necessary, to enhance patient care. This study provides valuable insights into the molecular characteristics of HER2-mutated NSCLC in a Brazilian population, highlighting the complexity and clinical relevance of these alterations. Larger studies are needed to clarify the prevalence and prognostic significance of HER2 mutations, as well as their impact on treatment response and survival. This knowledge is essential for advancing effective HER2-targeted therapies. The findings also support broader implementation of international clinical guidelines in Latin America and highlight the critical need to include underrepresented populations in cancer research. DOI - https://doi.org/10.18632/oncotarget.28737 Correspondence to - Fabio Tavora - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=hr5R9iDBFFI To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM
The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]
The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]
The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]
The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]
CARTA - Center for Academic Research and Training in Anthropogeny (Video)
The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]
CARTA - Center for Academic Research and Training in Anthropogeny (Video)
The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]
The human gut microbiome is tightly linked our health. Our analyses of diverse human populations from around the globe, ranging from hunter-gatherer to industrialized, show that the gut microbiome is profoundly influenced by lifestyle. With a large collaborative team, we conducted deep metagenomic sequencing of the gut microbiomes of Tsimane horticulturalists from Bolivia and compared them to those of Hadza hunter-gatherers from Tanzania. We are also investigating whether diet and microbial therapies can address deficiencies in the industrialized gut community. Molecular mechanisms of host-microbial interaction are pursued using an array of technologies and experimental approaches including gnotobiotic and conventional mouse models, quantitative imaging, and a metabolomics pipeline focused on investigating microbiota-dependent metabolites. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40698]
Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News. I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC. Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings. So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease. So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting. So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting. So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response. So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma. So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025. So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence. So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj. Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer. So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response. These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months. Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup. So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj. Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial. A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion. So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance. So, thank you, Jeanny, for joining me today and sharing your insights. And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics
On This Week in HPC, Addison Snell and Doug Eadline prep for ISC25, take a look at Intersect360 Research's new forecast, and talk about the partnership between Meta and Berkeley Labs.
BUFFALO, NY – June 24, 2025 – A new precision #oncology paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.” In this report, led by Alberto Hernando-Calvo from Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology; Razelle Kurzrock from WIN Consortium and Medical College of Wisconsin; Oncotarget Editor-in-Chief Wafik S. El-Deiry from WIN Consortium and Legorreta Cancer Center at Brown University; and corresponding author Shai Magidi, also from WIN Consortium, along with colleagues, describe the case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. After analysis, the WIN International Molecular Tumor Board proposed different personalized treatment plans based on the tumor's unique genetic mutations. This case highlights the growing role of precision oncology in guiding therapies for patients with treatment-resistant cancers. Colorectal cancer is one of the deadliest cancers worldwide, and managing advanced cases remains a significant challenge. This patient had already received five prior treatment regimens, including chemotherapy and targeted therapies. Although some treatments were initially beneficial, the cancer eventually developed resistance. Molecular analysis revealed key mutations in genes such as BRAF, MET, APC, TP53, and NRAS, which are often linked to aggressive tumor behavior and reduced treatment effectiveness. With limited standard options left, the patient's case was presented and reviewed by the WIN International Molecular Tumor Board, a global panel of cancer experts. The team analyzed the clinical history and genetic profile to design new treatment approaches. These involved off-label drug combinations tailored to the specific mutations found in the tumor. For example, one approach combined trametinib, a drug that blocks cancer cell growth signals, with amivantamab, an antibody that attacks cancer-related proteins MET and EGFR, and regorafenib, which helps cut off blood supply to tumors and may counteract effects from APC and TP53 mutations. “Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily.” This case reflects a shift in cancer care from standardized protocols to precision approaches, where therapy is selected based on a tumor's molecular features. Such strategies aim to delay resistance and slow disease progression more effectively. The WIN International Molecular Tumor Board also discussed practical challenges, including access to medications, combining off-label drugs, and the difficulties of enrolling patients in clinical trials after multiple prior treatments. Although the ultimate treatment decision remained with the patient's physician, this report shows how international collaboration and precision oncology can expand options for patients facing limited alternatives. It also emphasizes the value of repeat genetic analysis during disease progression to monitor new mutations in the tumor that may impact treatment. While the patient ultimately died from cancer progression, this case serves as a model for how molecular analysis and expert input can be used to guide treatment even in complex and metastatic colorectal cancer. As personalized cancer strategies continue to evolve, they may offer potential pathways for patients who have exhausted standard treatment options. DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - shai.magidi@winconsortium.org Video short - https://www.youtube.com/watch?v=uWDtWNgpK7A To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM
Drs Kaniksha Desai and Jennifer Sipos discuss molecular marker testing in the evaluation of thyroid nodules. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/index/list_15483_0
Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science
Seth Diehl, our newest Ortho rep, joins me today to walk us through what makes the Ortho Molecular products exceptionally high quality and why they are our top choice. He explains how Ortho Molecular Products is the only remaining practitioner and supplement manufacturer and the only company that has not sold out. We also dive into our latest products, Choline Support, L-Theanine, Inositol Complex, Estro Support, Milk Thistle, and Neuro Support Magnesium. The benefits of combining L-Theanine with your morning coffee: It reduces the jittery caffeine excitement It provides a relaxed energy boost It supports GABA, the most calming neurotransmitter Seth Diehl's Bio: Seth Diehl is an Account Executive with Ortho Molecular Products, proudly supporting healthcare practitioners throughout Iowa, including myself and the exceptional team at Integrative Health and Hormone Clinic. Seth earned both his Bachelor's in Biology and Master's in Biomedical Sciences from Iowa State University. Initially unfamiliar with integrative and functional medicine, Seth quickly became an enthusiastic advocate after discovering the impactful role preventative approaches play in overall health. Today, he combines his scientific expertise with a genuine passion for wellness, providing healthcare professionals with tailored health solutions and proactive patient care strategies. Seth feels privileged to collaborate with practitioners across his home state, backed by an organization that supports the transformation of the practice of medicine alongside integrative and functional medicine providers nationwide. In this episode: What differentiates Ortho Molecular Products from the rest, making them the best supplement manufacturer? How they use trademarked and patented raw materials throughout their product lines to ensure therapeutic outcomes Why you need to be careful when following the advice of influencers on social media- especially those with no background in healthcare How Ortho Molecular Products safeguards its manufacturing processes by adhering to FDA regulations for its food and pharmaceutical products How Choline Support supports cellular and mitochondrial membranes for better brain health and more energy How L-Theanine reduces stress and promotes relaxation without causing drowsiness How the unique form of magnesium in Neuro Magnesium Support improves sleep quality and memory and reduces brain fog How our new product, Inositol Complex, can be used to address the symptoms of PCOS How Estro Support helps women manage their menopause symptoms How Milk Thistle aids liver detoxification Links and Resources: Use code ENERGY to get 10% off MITOCHONDRIAL COMPLEX Use code TURMERIC to get 10% off TURMERIC Try Halo (Salt) Therapy for respiratory and skin health. Call 319-363-0033 to schedule your session. Relative Links for This Show: Neuro Magnesium Support L-Theanine – 60 capsules Use code PODCAST for 10% off your next supplement purchase Inositol Complex Choline Support EstroSupport Follow Your Longevity Blueprint On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online Follow Dr. Stephanie Gray On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast
Stephen Wolfram answers questions from his viewers about the future of science and technology as part of an unscripted livestream series, also available on YouTube here: https://wolfr.am/youtube-sw-qaTopics discussed: The limits and future of software defined everything - Molecular design and biological engineering - Human enhancement and genome level modification
An awe-inspiring journey into the world of proteins--how they shape life, and their remarkable potential to heal our bodies and our planet. Each fall, a robin begins the long trek north from Gibraltar to her summer home in Central Europe. Nestled deep in her optic nerve, a tiny protein turns a lone electron into a compass, allowing her to see north in colors we can only dream of perceiving. Taking us beyond the confines of our own experiences, The Color of North: The Molecular Language of Proteins and the Future of Life (Belknap Press, 2025) traverses the kingdom of life to uncover the myriad ways that proteins shape us and all organisms on the planet. Inside every cell, a tight-knit community of millions of proteins skillfully contorts into unique shapes to give fireflies their ghostly glow, enable the octopus to see predators with its skin, and make humans fall in love. Collectively, proteins orchestrate the intricate relationships within ecosystems and forge the trajectory of life. And yet, nature has exploited just a fraction of their immense potential. Shahir S. Rizk and Maggie M. Fink show how breathtaking advances in protein engineering are expanding on nature's repertoire, introducing proteins that can detect environmental pollutants, capture carbon dioxide from the atmosphere, and treat diseases from cancer to COVID-19. Weaving together themes of memory, migration, and family with cutting-edge research, The Color of North unveils a molecular world in which proteins are the pulsing heart of life. Ultimately, we gain a new appreciation for our intimate connections to the world around us and a deeper understanding of ourselves. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
The creation of a landmark gene editing drug used to treat a baby with a rare genetic mutation which could help transform personalized medicine. Blood tests showed baby KJ had sky-high levels of ammonia, a toxic substance the body usually expels. The root cause was his genes - or more particularly a specific gene mutation. The race was on to try and treat him before his condition took a firm hold. His doctors came up with a radical solution - for the first time ever, they designed and applied a gene-editing drug in record time, specifically for him. Have we seen breakthrough in preventing genetic diseases? With Fyodor Urnov, a professor in the Molecular and Cell Biology Department at the University of California, Virginijus Šikšnys professor at the Life Science Center of Vilnius University, Waseem Qasim from the UCL Institute of Child Health in Great Ormond Street Hospital in London and Jennifer Doudna, Professor, University of California, Berkeley and founder of the Innovative Genomics Institute. Presented by Tanya Beckett. Produced by Bob Howard. Researched by Mauve Schaffer Edited by Tara McDermott.
Feel like your body's no longer responding the way it used to—despite doing everything “right”? In this episode, we're diving into the world of bioactive peptides: what they are, how they work, and why they're becoming a game changer for women over 35 dealing with fatigue, muscle loss, inflammation, and hormone shifts. We break down the science behind Make Wellness peptides and how they help your body heal, rebuild, and thrive from the inside out. Hosted by Leanne Vogel. Coaching and other supports available at: https://shop.healthfulpursuit.com/ Podcast Sponsors, links and offers available at: https://www.healthfulpursuit.com/podcast/ Bioactive Peptides: https://www.healthfulpursuit.com/make
Garrett Butler, MD. Husband, father, son, friend, and family doc in rural WV. Undergraduate in Physics from Johns Hopkins University. Undergraduate in Molecular and Cell Biology from Towson University. MD from West Virginia University School of Medicine. Family Medicine residency at WVU SOM. Hospitalist at Vandalia Health Davis Medical Center. Outpatient family physician at Vandalia Health Broaddus Family Care. Hospitalist at Vandalia Health Broaddus Hospital. Medical director of Mansfield Place nursing home. Work With Us: Arétē by RAPID Health Optimization Links: Dr. Garrett Butler - Old Fellow Manor Anders Varner on Instagram Doug Larson on Instagram Coach Travis Mash on Instagram
© 2020-2025 Ivy Podcast Discovery LLC
